Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2320525 | 0.64 | GAA (0.36) | GAAMAPTALOX15HSD17B10 | |
| SCHEMBL19679 | 0.64 | — | — | |
| SCHEMBL23152 | 0.64 | — | — | |
| SCHEMBL160159 | 0.60 | GAA (0.38) | GAAMAPTALOX15HSD17B10 | |
| SCHEMBL8535074 | 0.60 | GAA (0.37) | GAAMAPTALOX15HSD17B10 | |
| SCHEMBL34295 | 0.60 | GAA (0.48) | GAAMAPTALOX15HSD17B10 | |
| SCHEMBL29415525 | 0.60 | GAA (0.48) | GAAMAPTALOX15HSD17B10 | |
| Hydrochloric Acid SCHEMBL9047476 | 0.59 | GAA (0.46) | GAAMAPTALOX15HSD17B10 | |
| Potassium SCHEMBL9683518 | 0.59 | GAA (0.46) | GAAMAPTALOX15HSD17B10 | |
| Bromide SCHEMBL8857359 | 0.59 | GAA (0.46) | GAAMAPTALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110245156-A1 | NOVEL ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | CYTOKINE PHARMASCIENCES, INC. (US) | 2011-10-06 | — | — | US | claimed |
| WO-2010077740-A2 | NOVEL ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | CYTOKINE PHARMASCIENCES, INC. (US) | 2010-07-08 | — | — | WO | claimed |
| US-20110245156-A1 | NOVEL ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | CYTOKINE PHARMASCIENCES, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| WO-2010077740-A2 | NOVEL ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | CYTOKINE PHARMASCIENCES, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| EP-0013612-B1 | (PIPERIDINYLALKYL)QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | JANSSEN PHARMACEUTICA N.V. (BE) | 1983-11-09 | — | — | EP | disclosed |
| EP-0014402-A1 | Novel 20-0-acylmaytansinoids, process for their preparation and pharmaceutical compositions containing them | Takeda Chemical Industries, Ltd. (JP) | 1980-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245156-A1 | NOVEL ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | DDX5, SAMHD1, EIF2AK2 | GAA 180/4885MAPT 3981/4885ALOX15 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.